-
German rail regulator backs Italian firm in competition spat
-
Pope appeals to Catholic traditionalists to avoid schism
-
Ancelotti shows Brazil his worth at World Cup but concerns remain
-
US Supreme Court upholds transgender sports bans
-
Stocks rise, yen at 40-year low against dollar
-
US Supreme Court rejects Trump bid to restrict birthright citizenship
-
Australia hold West Indies to 125-7 in World Cup semi-final
-
Serena set for remarkable Wimbledon return, Swiatek survives scare
-
Defending champ Swiatek survives scare to reach Wimbledon second round
-
Africa EV firm Spiro accused of torturing Uganda employees
-
US Supreme Court upholds state bans on transgender athletes in school
-
PSG's Portugal forward Ramos signs five-year AC Milan deal
-
Tourists soldier on in Rome despite heatwave
-
Inflation slows in top eurozone economies as ECB ponders next move
-
Record number of 'new millionaires' in 2025, says UBS
-
Starmer boosts budget to modernise UK military before exit
-
UN calls for food, shelter to help Venezuela quake survivors
-
Stocks mostly higher, yen stays near 40-year low against dollar
-
Merz faces mockery over praise of Germany's World Cup team
-
Data centres emitting more CO2 than thought: study
-
Ride-share group BlaBlaCar taps AI for 20-country expansion
-
Over 1 million migrants apply for Spain's mass regularisation
-
Escaping heat, forgetting war: Kyiv locals hit the beach
-
Germany questions footballing identity after fresh World Cup failure
-
Thousands march to demand illegal migrants leave South Africa
-
MEXC Lists Ondo's Tokenized Strategy Preferred Stock on Spot Market
-
Serena set for remarkable Wimbledon return
-
Stocks climb, yen stays near 40-year low against dollar
-
Outgoing UK PM Starmer announces 'record' defence spending
-
Swim star Marchand limps out of French nationals as Europeans loom
-
Paralluelo joins Barca women's departures
-
UN says transport infrastructure must adapt to climate
-
Police hunt for Monaco bomb suspect after Ukrainian-born businessman wounded
-
Sommer, Acerbi, Darmian, De Vrij leave Inter Milan
-
Sommer, Acerbi, Darmian leave Inter Milan
-
Germany's labour market dilemma: rising unemployment despite vacancies
-
'Waiting like torture': Turks despair as Schengen visa delays mount
-
Skating allows Russian, Belarussians to return as neutrals
-
Venezuela rescuers in final push to find survivors as families mourn
-
Russian double Olympic figure skating champion Dmitriev dies aged 58
-
Over 1 million migrants apply for Spain's mass regularisation: PM
-
S. Africa deploys police as anti-migrant protests loom
-
Thousands from Philippine sect protest pro-Duterte senator's graft case
-
Monaco parcel bomb blast wounds Ukrainian oligarch
-
South Africa repatriations top 25,000 ahead of anti-immigrant ultimatum
-
Sweden face France's attacking firepower at the World Cup
-
Taiwan raids tech firms in China AI chip smuggling probe
-
Online same-sex romance series embrace AI 'freedom'
-
Morocco 'unstoppable' says coach after Netherlands thriller
-
New Oxford academic centre symbolises UK's big-donor era
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
P.Stevenson--AMWN